Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multivalent S2-subunit Vaccines Provide Broad Protection Against Clade 1 Sarbecoviruses

ABSTRACT: Multivalent S2-subunit Vaccines Provide Broad Protection Against Clade 1 Sarbecoviruses

PROVIDER: PRJNA1187638 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31385906.fastq.gz	Fastqsanger.gz
	SRR31385907.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Multivalent S2-subunit Vaccines Provide Broad Protection Against Clade 1 Sarbecoviruses

Project description:The continuing emergence of immune evasive SARS-CoV-2 variants and the previous SARS-CoV-1 outbreak have accentuated the need for broadly protective sarbecovirus vaccines. Targeting the conserved S2-subunit of SARS-CoV-2 is a particularly promising approach to elicit broad protection. Here, expanding on our previous work with S2-based vaccines, we developed a nanoparticle vaccine displaying multiple copies of the SARS-CoV-1 S2 subunit. This vaccine alone, or as a cocktail with a SARS-CoV-2 S2 subunit vaccine, protected female transgenic K18-hACE2 mice from challenges with Omicron subvariant XBB as well as several sarbecoviruses identified as having pandemic potential including the bat sarbecovirus WIV1, BANAL-236, and a pangolin sarbecovirus. Challenge studies in female Fc- receptor knockout mice revealed that antibody-based cellular effector mechanisms played a role in protection elicited by these vaccines. These results demonstrate that our S2-based vaccines provide broad protection against clade 1 sarbecoviruses and offer insight into the mechanistic basis for protection.

2024-11-21 | GSE282247 | GEO

Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses.

Project description: Not available

| S-EPMC9651965 | biostudies-literature

Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge

Project description:Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge

| PRJNA953973 | ENA

Administration of multivalent influenza virus recombinant hemagglutinin vaccine in combination-adjuvant elicits broad reactivity beyond the vaccine components

Project description:Combining variant antigens into a multivalent vaccine is a traditional approach used to provide broad coverage against antigenically variable pathogens, such as polio, human papilloma and influenza viruses. However, strategies for increasing the breadth of antibody coverage beyond the vaccine are not well understood, but may provide more anticipatory protection. Influenza virus hemagglutinin (HA) is a prototypic variant antigen. Vaccines that induce HA-specific neutralizing antibodies lose efficacy as amino acid substitutions accumulate in neutralizing epitopes during influenza virus evolution. Here we studied the effect of a potent combination adjuvant (CpG/MPLA/squalene-in-water emulsion) on the breadth and maturation of the antibody response to a representative variant of HA subtypes H1, H5 and H7. Using HA protein microarrays and antigen-specific B cell labelling, we show when administered individually, each HA elicits a cross-reactive antibody profile for multiple variants within the same subtype and other closely-related subtypes (homosubtypic and heterosubtypic cross-reactivity, respectively). Despite a capacity for each subtype to induce heterosubtypic cross-reactivity, broader coverage was elicited by simply combining the subtypes into a multivalent vaccine. Importantly, multiplexing did not compromise antibody avidity or affinity maturation to the individual HA constituents. The use of adjuvants to increase the breadth of antibody coverage beyond the vaccine antigens may help future-proof vaccines against newly-emerging variants.

2021-06-26 | GSE178932 | GEO

A multivalent mRNA vaccine elicits robust immune responses and confers protection in a murine model of monkeypox virus infection

Project description:We developed two multivalent mRNA vaccines that induced strong immune responses and provided protection against monkeypox virus in mice. Additionally, we used single-cell RNA sequencing and V(D)J sequencing to explore the postvaccination immune landscape at the single-cell level and revealed B-cell receptor and T-cell receptor diversity, gene rearrangement, and predicted CDR3 motifs, systematically exploring the post-vaccination immune landscape at the single-cell level. These findings are poised to guide future vaccine design and present an innovative clinical strategy against monkeypox and orthopoxvirus outbreaks.

2024-09-15 | GSE276667 | GEO

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.

Project description: Not available

| S-EPMC9176361 | biostudies-literature

S2 Peptide-Conjugated SARS-CoV-2 Virus-like Particles Provide Broad Protection against SARS-CoV-2 Variants of Concern.

Project description: Not available

| S-EPMC11209314 | biostudies-literature

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Project description: Not available

| S-EPMC1564176 | biostudies-literature

Clade

Project description:Clade